The application of positron emission tomography (PET) imaging of brain amyloid or cerebrospinal fluid (CSF) measures of amyloid and tau in clinical practice to confirm an underlying Alzheimer’s disease process has been very limited due to patient cost and restricted access; processes for identifying and referring individuals living with dementia into clinical trials have been inefficient; and very few clinics have had the resources or expertise to provide cognitive interventions, post-diagnostic support or other evidence-based non-pharmacological interventions [6]. Here, MAPT is linked to Alzheimer disease.